2024
Circulating microRNAs in association with pancreatic cancer risk within 5 years
Wang C, Cai H, Cai Q, Wu J, StolzenbergāSolomon R, Guo X, Zhu C, Gao Y, Berlin J, Ye F, Zheng W, Setiawan V, Shu X. Circulating microRNAs in association with pancreatic cancer risk within 5 years. International Journal Of Cancer 2024, 155: 519-531. PMID: 38602070, PMCID: PMC11214275, DOI: 10.1002/ijc.34956.Peer-Reviewed Original ResearchPancreatic cancer riskCancer riskOdds ratioCohort studyAssociated with pancreatic cancer riskSouthern Community Cohort StudyYears prior to cancer diagnosisOvarian Cancer Screening TrialConfidence intervalsYears prior to diagnosisMultiethnic Cohort StudyCommunity Cohort StudyCancer Screening TrialConditional logistic regression analysisMen's Health StudyCase-control pairsProspective cohort studyCase-control studyCancer screeningLogistic regression analysisHealth StudyScreening TrialStratified analysisCancer diagnosisDiscovery stage
2023
Baseline Features and Reasons for Nonparticipation in the Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Study, a Colorectal Cancer Screening Trial
Robertson D, Dominitz J, Beed A, Boardman K, Del Curto B, Guarino P, Imperiale T, LaCasse A, Larson M, Gupta S, Lieberman D, Planeta B, Shaukat A, Sultan S, Menees S, Saini S, Schoenfeld P, Goebel S, von Rosenvinge E, Baffy G, Halasz I, Pedrosa M, Kahng L, Cassim R, Greer K, Kinnard M, Bhatt D, Dunbar K, Harford W, Mengshol J, Olson J, Patel S, Antaki F, Fisher D, Sullivan B, Lenza C, Prajapati D, Wong H, Beyth R, Lieb J, Manlolo J, Ona F, Cole R, Khalaf N, Kahi C, Kohli D, Rai T, Sharma P, Anastasiou J, Hagedorn C, Fernando R, Jackson C, Jamal M, Lee R, Merchant F, May F, Pisegna J, Omer E, Parajuli D, Said A, Nguyen T, Tombazzi C, Feldman P, Jacob L, Koppelman R, Lehenbauer K, Desai D, Madhoun M, Tierney W, Ho M, Hockman H, Lopez C, Carter Paulson E, Tobi M, Pinillos H, Young M, Ho N, Mascarenhas R, Promrat K, Mutha P, Pandak W, Shah T, Schubert M, Pancotto F, Gawron A, Underwood A, Ho S, Magno-Pagatzaurtundua P, Toro D, Beymer C, Kaz A, Elwing J, Gill J, Goldsmith S, Yao M, Protiva P, Pohl H, Kyriakides T, Kleiner E, Sullivan K, O'Leary J, Chiu W, Huang H, Russo J, Johnson G, Antonelli P, Burns A, Peduzzi P, Ciarleglio M, O'Connor T, Wallace R, Williams A, Tommessilli L, Taylor S, Pitts S, Mancini L, O'Brien P, O'Neil S, Perry M, McBride V, Carr W, Joncas C, O'Donnell E, Sather M, Warren S, Conner T, Honstein E, Sutton T, Putnam T, Branham K, Argyres D, Peterson D, Kennedy A, Carrick T, Apodaca C, Eden G, Martinez T, Tripp C, Nicholson M, Schwartz A, Felix M, Ward A, Marquez L, Lovato K, Cochran N, Tapia S, VanRaden M, Badgett C, Taylor Z, Pontzer J, Dorman B, Chavez M, Georg S, Templton T, Calais L, Haakensen C, Curtis B, Prehoda M, Colling C, Older D, Apodaca G, Sova J, Klee M, Wolfram-Aduan A, Ulatowski M, Hamilton B, Bopp (Formerly England) K, Ford G, Lace N, McDonnell W, Piehl G, Patel-Ejarque N, Berry M, Strubeck E, Chesnut L, Burridge L, Bean J, Kowal L, Voorhees (Formerly Rose) A, Ridley A, Croteau H, Bessett K, Fletcher C, Barbaresso M, Drummond A, Belanger K, McRobert E, Myers A, Trumble E, Rose P, Biswas A, Enache E, Shankin M, Strunk D, Simpson A, Harrison M, Prasad M, Robinson P, Flores A, Jananeh S, Tanukonda S, Ahmadi-Izadi G, Madihi S, Raufman J, Grady D, Britton A, Goldstein C, Thomas M, Lee V, Belizaire M, Costa C, Davis S, Decker M, Marrama A, Gilroy-Fanaras D, Gass J, Reece S, Tobin D, Carroll R, Ferreira M, Irvin D, Morken V, Covelli M, Medina T, Schiebel F, Shreves A, Shriver D, Frederick Y, Postle (formerly Matheny) C, Shaw J, Pastor D, Armstrong A, Kumaran V, Pinto A, Marshall V, McLarty S, Carlton J, Murphy K, McLemore K, Mortensen E, LePage J, Willis C, Berman K, Dunn T, Espinoza J, Schleski E, Shrader S, Gropp K, Kanaan Z, Miller L, Anees M, Judd S, Berchou V, Balogh D, Jones E, Covert K, Davis Y, Marbury C, Rambus M, Olgren E, Gellad Z, Sullivan B, Day T, Teehan S, Peters L, Hernandez-Chavez R, Murphy E, Cherry J, Graham E, Johnson J, Wooten W, Trujillo J, Harris M, Alizadeh M, Lo M, Sultan S, Brown L, Koster L, LeLaurin J, Irwin A, Kay N, Mckillip S, Lowe M, Yeralan S, Leehey D, McBurney C, Jain A, Park T, Broadwater L, El-Serag H, Shaib Y, Taylor E, Nair P, Broussard E, Gibson E, Hawkins R, Natividad T, Courtade D, Palmer M, Martinez S, Panagiotis K, Morrow C, Ballard C, Barker B, Garner M, McCalley S, Schwartzkopf A, Wright A, Titi M, Higbee A, Pratiksha S, Jones A, Shipe T, McKee J, Vennalaganti R, Terrey K, Maruf L, Brown D, Crouse E, Marchant-Miros K, Ussery B, Ducker L, Estell J, Porchia S, Kim M, Kim C, Chan B, Hayton A, Christiansen H, Peterson M, Ding G, Simpson V, Read S, Mamani G, Salazar J, Kato J, Bowie M, Carnevale R, Halim M, Sahagian A, Ibarra A, Travis Z, Garcia J, Gill A, Starzyk J, Sumarli S, Johnson V, Peresuh S, Quimby T, Cordova R, Herold L, Hawley A, Goo T, Kidao J, Lee R, Freidel C, Gutierrez E, Noorisharghi N, Ivie G, Jawish T, Partin S, Yoo G, Fabilane C, Noori N, Lang E, Senen S, Partin S, Fathi M, Chauvin R, Feiger J, Reataza M, Morgan T, Asghar A, Jacobs J, Kashefi M, May F, Ohning G, Padua D, Smutko V, Oh D, Kosoyan H, Dreskin B, Luu K, Alas A, Bharath P, Dixit V, Sanford** D, Vu J, Kadi S, Nwajuaku T, Smith J, Kincaid J, Mir M, Lanceta J, Rice J, Agarwal P, Augustine A, Prickel H, Vue J, Guerrero K, Levenson S, Aguilera-Fish A, Chestnut L, Jobse B, Lombardo C, Silver T, Ahmed N, Bockhold K, Koppelman R, Carneiro F, Garcia-Morales R, Spector D, Gomez J, Lehenbauer K, Reinink A, Anway R, Evans-Lindquist M, Eggers T, Green M, Pretti A, Meyeraan T, Condon D, Cavanagh M, DeFalco C, Cutting J, Joseph K, Dean S, Mitchell S, Phillips V, Krueger C, Zink D, Goldberg K, Patel N, Martinez Gonzalez M, Davis-Underwood H, O'Sullivan A, Suppes T, Bratcher K, Stern D, Wu R, Damisa J, Warsi R, Nguyen T, Pinillos H, Flowers E, Kuramoto A, Thurmond C, Orozco L, Farrell G, Jaynes R, Saenz P, Perez C, Collins J, Lin E, Onstad L, Pitts A, Osborn K, Kenworthy-Heinige T, Casey A, Gold D, Olivo C, Joos S, Subramanian S, Forro V, Cannady A, Usih J, Raitt M, Flynn M, Shittu Y, Jawaid M, Anderson R, Poole D, Butler C, Snead L, Christine H, Swanson G, Heumann D, Pandak W, Spataro J, Bajaj J, Solomon C, Smith Gilles H, Zafass A, Tilak S, Fuchs M, Davis M, Blackman L, Lemler J, Munsey R, Deebo J, McCarthy J, Noel M, Hurley R, Zurowski W, Sharpe A, Wilson K, Peets R, Lorenso B, Burrison S, Johnson D, Angelovic A, Erickson N, Hanson H, Bailey T, Genung K, Dulin H, Neuharth R, Clegg D, Velarde K, Dever J, Murphy M, Beck D, Wasil M, Vazquez J, O'Neil E, Ganji G, Ducom J, Lee M, Hovespians R, Margolis J, Simmons B, Sweeney (formerly St. Martin) J, Henry R, Martin-Ortiz J, Santiago-Rivera L, Gonzalez - Aviles G, Pedrosa C, Bird-Caceres J, Padilla B, Baez-Corujo F, Martinez- Ortiz Y, Vazquez E, Grigg-Gutierrez N, Laboy-Olivieri C, Urbina-Velez R, Andrews S, Rosa-Cruz S, Tirado-Montijo R, Otero-Aponte K, Martinez-Martino M, Freire A, Soto-Ramos A, Santana-Perez M, Araujo J, Vanderwarker C, Alexander J, Nevins E, LaGuire J, Guerrero L, Piehl G, Jenkins M, Chen T, Jang J, Tanus A, McKelvy P, Sayuk G, Chandiramani P, Vargo (Formerly Shoults) L, Vargo K, Lawrence S, Blythe K, Goldsmith S, Campbell R, Craddock M, Amodeo D, Reinhard R, Durant B, Wells B, Zoble A, Papademetriou M, Roche N, Adler P, Krishna A, Glaze D, Wijegunawardana D, Yeroushalmi S, Laine L, Mautner R, Bugaj J, Anderson J, Croteau H, Kingman L, Burridge L. Baseline Features and Reasons for Nonparticipation in the Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Study, a Colorectal Cancer Screening Trial. JAMA Network Open 2023, 6: e2321730. PMID: 37432690, PMCID: PMC10336619, DOI: 10.1001/jamanetworkopen.2023.21730.Peer-Reviewed Original ResearchConceptsFecal immunochemical testImmunochemical testEligible individualsAnnual fecal immunochemical testColorectal Cancer Screening TrialScreening testVeterans Affairs Medical CenterAverage CRC riskCancer Screening TrialCancer mortality outcomesCross-sectional studySpecific screening testCase report formsColorectal Cancer StudyStudy participant characteristicsCross-sectional analysisStool testingCRC riskMortality outcomesColorectal cancerClinical trialsCONFIRM studyMedical CenterScreening preferencesHispanic ethnicityRisk prediction models for endometrial cancer: development and validation in an international consortium
Shi J, Kraft P, Rosner B, Benavente Y, Black A, Brinton L, Chen C, Clarke M, Cook L, Costas L, Dal Maso L, Freudenheim J, Frias-Gomez J, Friedenreich C, Garcia-Closas M, Goodman M, Johnson L, La Vecchia C, Levi F, Lissowska J, Lu L, McCann S, Moysich K, Negri E, O'Connell K, Parazzini F, Petruzella S, Polesel J, Ponte J, Rebbeck T, Reynolds P, Ricceri F, Risch H, Sacerdote C, Setiawan V, Shu X, Spurdle A, Trabert B, Webb P, Wentzensen N, Wilkens L, Xu W, Yang H, Yu H, Du M, De Vivo I. Risk prediction models for endometrial cancer: development and validation in an international consortium. Journal Of The National Cancer Institute 2023, 115: 552-559. PMID: 36688725, PMCID: PMC10165481, DOI: 10.1093/jnci/djad014.Peer-Reviewed Original ResearchConceptsNurses' Health StudyRisk prediction modelNHS IIEndometrial cancerHealth StudyGenetic factorsEndometrial cancer incidence ratesOvarian Cancer Screening TrialCancer risk prediction modelsEndometrial Cancer ConsortiumPostmenopausal white womenCancer Screening TrialCancer risk stratificationCase-control studyRisk factor distributionCancer incidence ratesRelative risk estimatesEpidemiologic modelHeterogeneous study populationsPublic health practiceProphylactic hysterectomyRisk stratificationEpidemiologic factorsIncidence rateSelect cohort
2020
Population-Based Screening for Endometrial Cancer: Human vs. Machine Intelligence
Hart GR, Yan V, Huang GS, Liang Y, Nartowt BJ, Muhammad W, Deng J. Population-Based Screening for Endometrial Cancer: Human vs. Machine Intelligence. Frontiers In Artificial Intelligence 2020, 3: 539879. PMID: 33733200, PMCID: PMC7861326, DOI: 10.3389/frai.2020.539879.Peer-Reviewed Original ResearchAverage-risk womenEndometrial cancerRisk womenOvarian Cancer Screening TrialEndometrial cancer riskCancer Screening TrialPrimary care physiciansPopulation-based screeningCancer risk predictionHealth dataCare physiciansGynecologic oncologistsRisk stratificationDisease onsetPositive rateIndividual patientsCancer riskInvasive proceduresScreening TrialPersonal health dataEarly cancer detectionMortality rateEarly screeningFalse positive ratePrevious risk models
2019
Stratifying Ovarian Cancer Risk Using Personal Health Data
Hart GR, Nartowt BJ, Muhammad W, Liang Y, Huang GS, Deng J. Stratifying Ovarian Cancer Risk Using Personal Health Data. Frontiers In Big Data 2019, 2: 24. PMID: 33693347, PMCID: PMC7931902, DOI: 10.3389/fdata.2019.00024.Peer-Reviewed Original ResearchOvarian cancer riskCancer riskOvarian Cancer Screening TrialNational Health Interview SurveyCancer Screening TrialHigh-risk populationHealth Interview SurveyHealth dataOvarian cancer detectionDifferent risk categoriesPublic health organizationsOvarian cancerScreening TrialGeneral populationLower riskPersonal health dataTargeted screeningGenetic testingRisk categoriesHealth OrganizationInterview SurveyCancerCharacteristic curveNon-invasive wayCancer detection
2018
Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community
Su C, Bhargava A, Shah C, Halmos B, Gucalp R, Packer S, Ohri N, Haramati L, Perez-Soler R, Cheng H. Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community. Clinical Lung Cancer 2018, 19: e767-e773. PMID: 29937386, DOI: 10.1016/j.cllc.2018.05.019.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedCarcinoma, Squamous CellCombined Modality TherapyDecision Support TechniquesEarly Detection of CancerFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMedically Underserved AreaMiddle AgedPrognosisRetrospective StudiesSmall Cell Lung CarcinomaSurvival RateTomography, X-Ray ComputedUrban PopulationConceptsUnited States Preventative Services Task Force guidelinesPrimary lung cancerTask Force guidelinesLung cancerScreening TrialMortality differencesPrimary care provider statusScreen-detected lung cancersNational Lung Screening TrialLung cancer-related mortalityLung Cancer Screening TrialActive smoking statusTime of diagnosisCancer Screening TrialCancer-related mortalityUnderserved communitiesUrban underserved communitiesLCS eligibilityCause mortalityPatient characteristicsProspective trialCurative treatmentSmoking statusSurgical managementCox regression
2017
Serum 25āhydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men
Layne TM, Weinstein SJ, Graubard BI, Ma X, Mayne ST, Albanes D. Serum 25āhydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men. Cancer 2017, 123: 2698-2704. PMID: 28369777, PMCID: PMC5498231, DOI: 10.1002/cncr.30634.Peer-Reviewed Original ResearchConceptsProstate cancer riskD binding proteinVitamin D statusCancer riskD statusOdds ratioProstate cancerLow vitamin D statusSerum DBPOvarian Cancer Screening TrialDecreased prostate cancer riskOverall prostate cancerCancer Screening TrialBlack menProstate cancer screeningApparent inverse associationConfidence intervalsVitamin D binding proteinConditional logistic regressionProstate cancer casesNonaggressive diseaseCohort entryCancer screeningBlood drawInverse association
2016
Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications
Gershman B, Van Houten HK, Herrin J, Moreira DM, Kim SP, Shah ND, Karnes RJ. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications. European Urology 2016, 71: 55-65. PMID: 26995328, DOI: 10.1016/j.eururo.2016.03.015.Peer-Reviewed Original ResearchConceptsRate of biopsyProstate-specific antigen (PSA) screeningPredictors of complicationsPostbiopsy complicationsUSPSTF recommendationsAntigen screeningProstate biopsyRelative morbidityScreening TrialUS Preventive Services Task Force (USPSTF) recommendationOvarian Cancer Screening TrialAmerican Urological Association guidelinesMorbidity of biopsyPrior fluoroquinolone useEuropean Randomized StudyCancer Screening TrialInterrupted time series analysisProportion of menTask Force recommendationsInfectious complicationsAnticoagulant useComplication rateUnderwent biopsyRandomized studyScreening guidelines
2014
PD19-12 MODIFIED GLEASON GRADE OF PROSTATIC ADENOCARCINOMAS DETECTED IN THE PROSTATE, LUNG, COLORECTAL, AND OVARIAN CANCER SCREENING TRIAL
Humphrey P, Strother M, Grubb R, Hickey T, Korch M, Riley T, Mabie J, Bellinger A, Andriole G. PD19-12 MODIFIED GLEASON GRADE OF PROSTATIC ADENOCARCINOMAS DETECTED IN THE PROSTATE, LUNG, COLORECTAL, AND OVARIAN CANCER SCREENING TRIAL. Journal Of Urology 2014, 191: e550. DOI: 10.1016/j.juro.2014.02.1531.Peer-Reviewed Original Research
2013
Dietary fat intake and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Arem H, Mayne ST, Sampson J, Risch H, Stolzenberg-Solomon RZ. Dietary fat intake and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Annals Of Epidemiology 2013, 23: 571-575. PMID: 23890797, PMCID: PMC3752990, DOI: 10.1016/j.annepidem.2013.06.006.Peer-Reviewed Original ResearchConceptsDietary fat intakePancreatic cancer riskOvarian Cancer Screening TrialCancer Screening TrialFat intakeCancer riskInverse associationPancreatic cancerScreening TrialCox proportional hazards regressionTotal fat intakeProportional hazards regressionObserved inverse associationPancreatic cancer casesHazards regressionCancer casesRisk associationUndetected diseasePossible reverse causationDietary changesIntakeReverse causationColorectalFat typeRisk
2011
Meat consumption and the risk of incident distal colon and rectal adenoma
Ferrucci LM, Sinha R, Huang WY, Berndt SI, Katki HA, Schoen RE, Hayes RB, Cross AJ. Meat consumption and the risk of incident distal colon and rectal adenoma. British Journal Of Cancer 2011, 106: 608-616. PMID: 22166801, PMCID: PMC3281548, DOI: 10.1038/bjc.2011.549.Peer-Reviewed Original ResearchConceptsDistal colorectal adenomaColorectal adenomasOdds ratioRectal adenomasOvarian Cancer Screening TrialSuggestive positive associationCancer Screening TrialMultivariate logistic regressionEarly colorectal carcinogenesisNitrate/nitriteScreening armDistal colonColorectal carcinogenesisEarly neoplasiaScreening TrialAdenomasLogistic regressionRed meatRole of meatSingle screeningConfidence intervalsPrevalent eventPositive associationHaeme ironMutagenic activityLarge Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status
Skates S, Mai P, Horick N, Piedmonte M, Drescher C, Isaacs C, Armstrong D, Buys S, Rodriguez G, Horowitz I, Berchuck A, Daly M, Domchek S, Cohn D, Van Le L, Schorge J, Newland W, Davidson S, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff N, Fabian C, Sluss P, Nayfield S, Kasten C, Finkelstein D, Greene M, Lu K. Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. Cancer Prevention Research 2011, 4: 1401-1408. PMID: 21893500, PMCID: PMC3172691, DOI: 10.1158/1940-6207.capr-10-0402.Peer-Reviewed Original ResearchConceptsHigh-risk womenCut-pointsMenopausal statusScreening TrialOvarian Cancer Screening TrialOvarian cancer screening studiesPopulation of high-risk womenOvarian cancer screeningPremenopausal womenStandard cut-pointCancer Screening TrialCancer screening studyEffect of menopausal statusPostmenopausal subjectsClinical factorsScreening studiesOral contraceptivesCancer screeningEarly detection of ovarian cancerCA125 testDetection of ovarian cancerGynecologic Oncology GroupEligibility criteriaScreening protocolDemographic data
2009
Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Ferrucci LM, Cross AJ, Graubard BI, Brinton LA, McCarty CA, Ziegler RG, Ma X, Mayne ST, Sinha R. Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. British Journal Of Cancer 2009, 101: 178-184. PMID: 19513076, PMCID: PMC2713710, DOI: 10.1038/sj.bjc.6605118.Peer-Reviewed Original ResearchConceptsOvarian Cancer Screening TrialCancer Screening TrialBreast cancerDietary ironMeat mutagensHazard ratioScreening TrialSubsequent breast cancer riskCox proportional hazards regressionInvasive breast cancer casesRed meatFood frequency questionnaireInvasive breast cancerQuintiles of intakeProportional hazards regressionHaem iron intakeIntake of meatBreast cancer riskConfidence intervalsBreast cancer casesHeterocyclic aminesFrequency questionnaireHazards regressionProspective studyIron intakeXenobiotic Metabolizing Gene Variants, Dietary Heterocyclic Amine Intake, and Risk of Prostate Cancer
Koutros S, Berndt SI, Sinha R, Ma X, Chatterjee N, Alavanja MC, Zheng T, Huang WY, Hayes RB, Cross AJ. Xenobiotic Metabolizing Gene Variants, Dietary Heterocyclic Amine Intake, and Risk of Prostate Cancer. Cancer Research 2009, 69: 1877-1884. PMID: 19223546, PMCID: PMC2662592, DOI: 10.1158/0008-5472.can-08-2447.Peer-Reviewed Original ResearchConceptsProstate cancer riskProstate cancerOdds ratioCancer riskSingle nucleotide polymorphismsDietary Heterocyclic Amine IntakeOvarian Cancer Screening TrialHeterocyclic amine intakeCancer Screening TrialUnconditional logistic regressionCase-control studyDietary heterocyclic aminesProstate cancer casesHeterocyclic aminesHCA intakeCancer casesLow intakeScreening TrialHCA metabolismMalignant transformationLogistic regressionCancerIntakeGene variantsConfidence intervals
2008
A note on bias due to fitting prospective multivariate generalized linear models to categorical outcomes ignoring retrospective sampling schemes
Mukherjee B, Liu I. A note on bias due to fitting prospective multivariate generalized linear models to categorical outcomes ignoring retrospective sampling schemes. Journal Of Multivariate Analysis 2008, 100: 459-472. PMID: 34194120, PMCID: PMC8240662, DOI: 10.1016/j.jmva.2008.05.011.Peer-Reviewed Original ResearchOutcome dependent samplingCase-control sampling designData exampleBias approximationCategorical outcomesSampling designOngoing ProstateDisease sub-classificationLogit linkDependent samplesGeneralized linear modelLinear modelEquivalenceResponse fallApproximate expressionExamplesApproximationCancer Screening TrialInferenceCase-control study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply